PLSE Pulse Biosciences Inc

Price (delayed)

$30.23

Market cap

$2.09B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.1

Enterprise value

$2.03B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 3

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first ...

Highlights
The company's revenue has surged by 115% QoQ
The gross margin has surged by 61% since the previous quarter
The quick ratio has dropped by 55% year-on-year and by 32% since the previous quarter
PLSE's equity is down by 44% year-on-year and by 18% since the previous quarter

Key stats

What are the main financial stats of PLSE

PLSE stock price

How has the Pulse Biosciences stock price performed over time
Intraday
-2.48%
1 week
5.4%
1 month
18.09%
1 year
103.3%
YTD
120.17%
QTD
9.02%

Financial performance

How have Pulse Biosciences's revenue and profit performed over time
Revenue
$751,000
Gross profit
-$158,000
Operating income
-$78.05M
Net income
-$74.57M
Gross margin
-21%
Net margin
-9,929%
The company's revenue has surged by 115% QoQ
The gross margin has surged by 61% since the previous quarter
The operating margin has soared by 53% from the previous quarter
The company's net margin has surged by 52% QoQ

Price vs fundamentals

How does PLSE's price correlate with its fundamentals

Growth

What is Pulse Biosciences's growth rate over time

Valuation

What is Pulse Biosciences stock price valuation
P/E
N/A
P/B
31
P/S
2,736.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,704.45
PLSE's EPS is down by 12% year-on-year
The P/B is 167% above the 5-year quarterly average of 11.6 and 120% above the last 4 quarters average of 14.1
PLSE's equity is down by 44% year-on-year and by 18% since the previous quarter
The company's revenue has surged by 115% QoQ

Efficiency

How efficient is Pulse Biosciences business performance
The ROIC has dropped by 56% year-on-year and by 13% since the previous quarter
PLSE's return on sales has surged by 52% since the previous quarter
PLSE's return on equity is down by 22% year-on-year and by 18% since the previous quarter
The ROA has contracted by 22% YoY and by 16% from the previous quarter

Dividends

What is PLSE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PLSE.

Financial health

How did Pulse Biosciences financials performed over time
The quick ratio has dropped by 55% year-on-year and by 32% since the previous quarter
PLSE's current ratio has plunged by 53% YoY and by 31% from the previous quarter
The company's debt is 89% lower than its equity
The debt to equity has soared by 57% YoY and by 22% from the previous quarter
PLSE's equity is down by 44% year-on-year and by 18% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.